CYTOKINETICS, INCORPORATED Net Cash Provided by (Used in) Investing Activities, Continuing Operations
CYTOKINETICS, INCORPORATED (CYTK) reported Net Cash Provided by (Used in) Investing Activities, Continuing Operations of $20.14 million for the 3-month period ending 2018-03-31, per its 10-Q filed 2018-05-10.
Discontinued › Cash Flow › Investing Activities
us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations · last filed 2018-05-10
- CYTOKINETICS, INCORPORATED net cash provided by (used in) investing activities, continuing operations for the quarter ending 2018-03-31 was $20.14M.
- CYTOKINETICS, INCORPORATED net cash provided by (used in) investing activities, continuing operations for the quarter ending 2017-12-31 was $30.76M.
- CYTOKINETICS, INCORPORATED net cash provided by (used in) investing activities, continuing operations for the quarter ending 2017-09-30 was $39.66M, a 183.86% increase year-over-year.
- CYTOKINETICS, INCORPORATED net cash provided by (used in) investing activities, continuing operations for the quarter ending 2017-06-30 was -$23.95M.
- CYTOKINETICS, INCORPORATED net cash provided by (used in) investing activities, continuing operations for fiscal 2017 was -$65.83M.
- CYTOKINETICS, INCORPORATED net cash provided by (used in) investing activities, continuing operations for fiscal 2016 was -$52.08M, a 424.20% decline from fiscal 2015.
- CYTOKINETICS, INCORPORATED net cash provided by (used in) investing activities, continuing operations for fiscal 2015 was $16.06M.
- CYTOKINETICS, INCORPORATED net cash provided by (used in) investing activities, continuing operations for fiscal 2014 was -$4.05M.
| Period end | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 3 month | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 6 month | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 9 month | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 12 month |
|---|---|---|---|---|
| 2018-03-31 | $20.14M 10-Q · filed 2018-05-10 | $50.90M derived: sum of 2 quarters · filed 2018-05-10 | $90.56M derived: sum of 3 quarters · filed 2018-05-10 | $66.61M derived: sum of 4 quarters · filed 2018-05-10 |
| 2017-12-31 | $30.76M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-05 | $70.42M derived: sum of 2 quarters · filed 2018-03-05 | $46.47M derived: sum of 3 quarters · filed 2018-03-05 | -$65.83M 10-K · filed 2018-03-05 |
| 2017-09-30 | $39.66M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-03 | $15.71M derived: sum of 2 quarters · filed 2017-11-03 | -$96.59M 10-Q · filed 2017-11-03 | -$138.56M derived: sum of 4 quarters · filed 2018-05-10 |
| 2017-06-30 | -$23.95M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-04 | -$136.25M 10-Q · filed 2017-08-04 | -$178.22M derived: sum of 3 quarters · filed 2018-05-10 | -$164.25M derived: sum of 4 quarters · filed 2018-05-10 |
| 2017-03-31 | -$112.30M 10-Q · filed 2018-05-10 | -$154.27M derived: sum of 2 quarters · filed 2018-05-10 | -$140.30M derived: sum of 3 quarters · filed 2018-05-10 | -$144.22M derived: sum of 4 quarters · filed 2018-05-10 |
| 2016-12-31 | -$41.97M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-05 | -$28.00M derived: sum of 2 quarters · filed 2018-03-05 | -$31.91M derived: sum of 3 quarters · filed 2018-03-05 | -$52.08M 10-K · filed 2018-03-05 |
| 2016-09-30 | $13.97M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-03 | $10.05M derived: sum of 2 quarters · filed 2017-11-03 | -$10.11M 10-Q · filed 2017-11-03 | $15.30M derived: sum of 4 quarters · filed 2018-03-05 |
| 2016-06-30 | -$3.92M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-04 | -$24.08M 10-Q · filed 2017-08-04 | $1.33M derived: sum of 3 quarters · filed 2018-03-05 | $12.64M derived: sum of 4 quarters · filed 2018-03-05 |
| 2016-03-31 | -$20.16M 10-Q · filed 2017-05-04 | $5.25M derived: sum of 2 quarters · filed 2018-03-05 | $16.56M derived: sum of 3 quarters · filed 2018-03-05 | $28.00M derived: sum of 4 quarters · filed 2018-03-05 |
| 2015-12-31 | $25.41M derived: 10-K 12 month − 10-Q/A 9 month · filed 2018-03-05 | $36.72M derived: sum of 2 quarters · filed 2018-03-05 | $48.16M derived: sum of 3 quarters · filed 2018-03-05 | $16.06M 10-K · filed 2018-03-05 |
| 2015-09-30 | $11.31M derived: 10-Q/A 9 month − 10-Q 6 month · filed 2016-12-15 | $22.75M derived: sum of 2 quarters · filed 2016-12-15 | -$9.35M 10-Q/A · filed 2016-12-15 | -$3.04M derived: sum of 4 quarters · filed 2017-03-06 |
| 2015-06-30 | $11.44M derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-04 | -$20.65M 10-Q · filed 2016-08-04 | -$14.35M derived: sum of 3 quarters · filed 2017-03-06 | -$4.28M derived: sum of 4 quarters · filed 2017-03-06 |
| 2015-03-31 | -$32.09M 10-Q · filed 2016-05-05 | -$25.79M derived: sum of 2 quarters · filed 2017-03-06 | -$15.72M derived: sum of 3 quarters · filed 2017-03-06 | -$7.28M derived: sum of 4 quarters · filed 2017-03-06 |
| 2014-12-31 | $6.30M derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-06 | $16.37M derived: sum of 2 quarters · filed 2017-03-06 | $24.81M derived: sum of 3 quarters · filed 2017-03-06 | -$4.05M 10-K · filed 2017-03-06 |
| 2014-09-30 | $10.07M derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-05 | $18.51M derived: sum of 2 quarters · filed 2015-11-05 | -$10.35M 10-Q · filed 2015-11-05 | -$4.54M derived: sum of 4 quarters · filed 2016-03-03 |
| 2014-06-30 | $8.44M derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-05 | -$20.42M 10-Q · filed 2015-08-05 | -$14.61M derived: sum of 3 quarters · filed 2016-03-03 | |
| 2014-03-31 | -$28.86M 10-Q · filed 2015-05-04 | -$23.05M derived: sum of 2 quarters · filed 2016-03-03 | ||
| 2013-12-31 | $5.81M derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-03 | -$1.52M 10-K · filed 2016-03-03 | ||
| 2013-09-30 | -$7.33M 10-Q · filed 2014-11-06 | |||
| 2012-12-31 | -$28.82M 10-K · filed 2015-03-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 |